The emergence of new therapeutic targets in pulmonary arterial hypertension: From now to the near future

Expert Review of Respiratory Medicine

Volumn 7, Issue 1, 2013, Pages 43-55

  Malenfant, Simon ^a   Margaillan, Guillaume ^a   Loehr, Jérémy Edwin ^a   Bonnet, Sébastien ^a   Provencher, Steeve ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

anti inflammatory therapy; dehydroepiandrosterone; endothelial dysfunction; microRNA; pulmonary arterial hypertension; pulmonary hypertension; therapeutic targets; tyrosine kinase inhibitors; vascular remodeling

Indexed keywords

FRACTALKINE; IMATINIB; MICRORNA; NILOTINIB; PRASTERONE; STAT3 PROTEIN;

ALGORITHM; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COMPETITIVE INHIBITION; ENDOTHELIAL DYSFUNCTION; ENERGY RESOURCE; EXERCISE; GENE THERAPY; GOLD STANDARD; HEART RIGHT VENTRICLE FAILURE; HEART STROKE VOLUME; HUMAN; LONG TERM SURVIVAL; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; LUNG VASCULAR RESISTANCE; NONHUMAN; OXYGEN SATURATION; PATHOPHYSIOLOGY; PATIENT REFERRAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REVIEW; VASOCONSTRICTION;

EID: 84873180886     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.12.83     Document Type: Review

References (130)

1. Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S43-S54 (2009).
2. Humbert M, Sitbon O, Chaouat A et al.Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173(9), 1023-1030 (2006).
3. Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur. Respir. J. 30(1), 104-109 (2007). (Pubitemid 47074013)
4. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A metaanalysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30(4), 394-403 (2009).
5. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N. Engl. J. Med. 351(14), 1425-1436 (2004).
6. Galiè N, Hoeper MM, Humbert M et al.; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 30(20), 2493-2537 (2009).
7. Mclaughlin VV, Langer A, Tan M et al. Contemporary trends in the diagnosis and management of pulmonary arterialhypertension: an initiative to close the care gap. Chest doi:10.1378/chest.11-3060 (2012) (Epub ahead of print).
8. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70(4), 580-587 (1984). (Pubitemid 14020655)
9. Rich S, Seidlitz M, Dodin E et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 114(3), 787-792 (1998). (Pubitemid 28433741)
10. Mereles D, Ehlken N, Kreuscher S et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 114(14), 1482-1489 (2006). (Pubitemid 44527003)
11. Grünig E, Lichtblau M, Ehlken N et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur. Respir. J. 40(1), 84-92 (2012).
12. Handoko ML, de Man FS, Happé CM et al. Opposite effects of training in rats with stable and progressive pulmonary hypertension. Circulation 120(1), 42-49 (2009).
13. Sitbon O, Humbert M, Jaïs X et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23), 3105-3111 (2005). (Pubitemid 40847788)
14. Rich S, Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J. Am. Coll. Cardiol. 18(5), 1323-1327 (1991).
15. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328(24), 1732-1739 (1993). (Pubitemid 23170122)
16. Galiè N, Olschewski H, Oudiz RJ et al.; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 117(23), 3010-3019 (2008).
17. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346(12), 896-903 (2002). (Pubitemid 34984638)
18. Galiè N, Rubin Lj, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630), 2093-2100 (2008). (Pubitemid 351902178)
19. Galiè N, Beghetti M, Gatzoulis MA et al.; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114(1), 48-54 (2006).
20. Iglarz M, Binkert C, Morrison K et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 327(3), 736-745 (2008).
21. Bruderer S, Hopfgartner G, Seiberling M et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 42(9), 901-910 (2012).
22. Bruderer S, Aänismaa P, Homery MC et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J. 14(1), 68-78 (2012).
23. Rubin L, Pulido T, Channick R et al. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): results from the SERAPHIN Trial. Chest 142(4), 1026A-1026A (2012).
24. Moncada S, Gryglewski R, Bunting S, Vane Jr. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263(5579), 663-665 (1976).
25. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am. J. Respir. Cell Mol. Biol. 26(2), 194-201 (2002). (Pubitemid 34107873)
26. Barst RJ, Rubin LJ, Long WA et al.; Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med. 334(5), 296-301 (1996). (Pubitemid 26033085)
27. Simonneau G, Barst RJ, Galie N et al.; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 165(6), 800-804 (2002). (Pubitemid 34229650)
28. McLaughlin VV, Benza RL, Rubin LJ et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J. Am. Coll. Cardiol. 55(18), 1915-1922 (2010).
29. Gomberg-Maitland M, Tapson VF, Benza RL et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 172(12), 1586-1589 (2005). (Pubitemid 43076550)
30. Olschewski H, Simonneau G, Galiè N et al.; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347(5), 322-329 (2002). (Pubitemid 34815354)
31. Barst RJ, McGoon M, McLaughlin V et al.; Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 41(12), 2119-2125 (2003). (Pubitemid 36724255)
32. Tapson VF, Torres F, Kermeen F et al. Oral Treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C Study): a randomized controlled trial. Chest 142(6), 1383-1390 (2012).
33. Sitbon O, Delcroix M, Bergot E et al. EPITOME-2, an open-label study evaluating a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from Flolan®. Am. J. Respir. Crit. Care Med. 185(A2500) (2012).
34. McLaughlin VV, Archer SL, Badesch DB et al.; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J. Am. Coll. Cardiol. 53(17), 1573-1619 (2009).
35. Simonneau G, Torbicki A, Hoeper MM et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment ofpulmonary arterial hypertension. Eur. Respir. J. 40(4), 874-880 (2012).
36. Galiè N, Ghofrani HA, Torbicki A et al.; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353(20), 2148-2157 (2005).
37. Galiè N, Brundage BH, Ghofrani HA et al.; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22), 2894-2903 (2009).
38. Evgenov OV, Busch CJ, Evgenov NV et al. Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 290(4), L723-L729 (2006). (Pubitemid 43725077)
39. Mittendorf J, Weigand S, Alonso-Alija C et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 4(5), 853-865 (2009).
40. Schermuly RT, Stasch JP, Pullamsetti SS et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur. Respir. J. 32(4), 881-891 (2008).
41. McLaughlin VV. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur. Respir. Rev. 20(122), 262-269 (2011).
42. Ghofrani HA, Hoeper MM, Halank M et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a Phase II study. Eur. Respir. J. 36(4), 792-799 (2010).
43. Zhu B, Wang L, Sun L, Cao R. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis. J. Cardiovasc. Pharmacol. 60(4), 342-346 (2012).
44. Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am. J. Cardiol. 108(8), 1177-1182 (2011).
45. Humbert M, Sitbon O, Chaouat A et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122(2), 156-163 (2010).
46. Paulin R, Courboulin A, Barrier M, Bonnet S. From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. J. Mol. Med. 89(11), 1089-1101 (2011).
47. Henning RJ, Sawmiller DR. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc. Res. 49(1), 27-37 (2001).
48. Dewachter L, Dewachter C, Naeije R. New therapies for pulmonary arterial hypertension: an update on current bench to bedside translation. Expert Opin. Investig. Drugs 19(4), 469-488 (2010).
49. Petkov V, Mosgoeller W, Ziesche R et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 111(9), 1339-1346 (2003). (Pubitemid 36554704)
50. Leuchte HH, Baezner C, Baumgartner RA et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur. Respir. J. 32(5), 1289-1294 (2008).
51. Rakotoniaina Z, Guerard P, Lirussi F et al. The protective effect of HMG-CoA reductase inhibitors against monocrotalineinduced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch. Pharmacol. 374(3), 195-206 (2006). (Pubitemid 44819252)
52. Girgis RE, Mozammel S, Champion HC et al. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. Lung Cell Mol. Physiol. 292(5), L1105-L1110 (2007). (Pubitemid 47084854)
53. Wilkins MR, Ali O, Bradlow W et al.; Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group. Simvastatin as a treatment for pulmonary hypertension trial. Am. J. Respir. Crit. Care Med. 181(10), 1106-1113 (2010).
54. Kawut SM, Bagiella E, Lederer DJ et al.; ASA-STAT Study Group. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation 123(25), 2985-2993 (2011).
55. Wang XX, Zhang FR, Shang YP et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J. Am. Coll. Cardiol. 49(14), 1566-1571 (2007).
56. Jurasz P, Courtman D, Babaie S, Stewart DJ. Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials. Pharmacol. Ther. 126(1), 1-8 (2010).
57. Klein M, Schermuly RT, Ellinghaus P et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 118(20), 2081-2090 (2008).
58. Perros F, Montani D, Dorfmüller P et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178(1), 81-88 (2008). (Pubitemid 351919196)
59. Dumitrescu D, Seck C, ten Freyhaus H, Gerhardt F, Erdmann E, Rosenkranz S. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur. Respir. J. 38(1), 218-220 (2011).
60. Blay JY. A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat. Rev. 37(5), 373-384 (2011).
61. Chen Y, Peng C, Li D, Li S. Molecular and cellular bases of chronic myeloid leukemia. Protein Cell 1(2), 124-132 (2010).
62. Ohno R. Changing paradigm of the treatment of Philadelphia chromosomepositive acute lymphoblastic leukemia. Curr. Hematol. Malig. Rep. 5(4), 213-221 (2010).
63. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 312(5777), 1175-1178 (2006). (Pubitemid 43801135)
64. Ghofrani HA, Morrell NW, Hoeper MM et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 182(9), 1171-1177 (2010).
65. ten Freyhaus H, Dumitrescu D, Berghausen E, Vantler M, Caglayan E, Rosenkranz S. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin. Investig. Drugs 21(1), 119-134 (2012).
66. Hoeper M, Barst RJ, Galié N et al. Imatinib in pulmonary arterial hypertension, a randomized efficacy study (IMPRES). Eur. Respir. J. 38, Abstract 413 (2011).
67. Peerzada MM, Spiro TP, Daw HA. Pulmonary toxicities of tyrosine kinase inhibitors. Clin. Adv. Hematol. Oncol. 9(11), 824-836 (2011).
68. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR; Imatinib-IPF Study Investigators. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 181(6), 604-610 (2010).
69. Ranieri G, Gadaleta-Caldarola G, Goffredo V et al. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr. Med. Chem. 19(7), 938-944 (2012).
70. Escudier B, Eisen T, Stadler WM et al.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007). (Pubitemid 46089673)
71. Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
72. Gomberg-Maitland M, Maitland ML, Barst RJ et al. A dosing/cross- development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. 87(3), 303-310 (2010).
73. Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 354(24), 2542-2551 (2006). (Pubitemid 43882350)
74. Golemovic M, Verstovsek S, Giles F et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin. Cancer Res. 11(13), 4941-4947 (2005). (Pubitemid 41557215)
75. O'Hare T, Walters DK, Stoffregen EP et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65(11), 4500-4505 (2005). (Pubitemid 40740783)
76. Verstovsek S, Golemovic M, Kantarjian H et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 104(6), 1230-1236 (2005). (Pubitemid 41278958)
77. Montani D, Bergot E, Günther S et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125(17), 2128-2137 (2012).
78. Pullamsetti SS, Berghausen EM, Dabral S et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 32(6), 1354-1365 (2012).
79. Rosenkranz S, Ikuno Y, Leong FL et al. Src family kinases negatively regulate platelet-derived growth factor α receptordependent signaling and disease progression. J. Biol. Chem. 275(13), 9620-9627 (2000). (Pubitemid 30185194)
80. Morrell NW, Adnot S, Archer SL et al. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(Suppl 1.), S20-S31 (2009).
81. Fagan KA, Oka M, Bauer NR et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am. J. Physiol. Lung Cell Mol. Physiol. 287(4), L656-L664 (2004). (Pubitemid 39249378)
82. McNamara PJ, Murthy P, Kantores C et al. Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide. Am. J. Physiol. Lung Cell Mol. Physiol. 294(2), L205-L213 (2008). (Pubitemid 351253358)
83. Barman SA. Vasoconstrictor effect of endothelin-1 on hypertensive pulmonary arterial smooth muscle involves Rho-kinase and protein kinase C. Am. J. Physiol. Lung Cell Mol. Physiol. 293(2), L472-L479 (2007). (Pubitemid 47205028)
84. Guilluy C, Eddahibi S, Agard C et al. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling. Am. J. Respir. Crit. Care Med. 179(12), 1151-1158 (2009).
85. Antoniu SA. Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. Expert Opin. Ther. Targets 16(4), 355-363 (2012).
86. Abe K, Shimokawa H, Morikawa K et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 94(3), 385-393 (2004). (Pubitemid 38240731)
87. Liu AJ, Ling F, Wang D, Wang Q, Lü XD, Liu YL. Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip via the ERK signal pathway. Chin. Med. J. 124(19), 3098-3104 (2011).
88. Fujita H, Fukumoto Y, Saji K et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 25(2), 144-149 (2010).
89. Jiang Y, Miyazaki T, Honda A et al. Apoptosis and inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway in the anti-proliferative actions of dehydroepiandrosterone. J. Gastroenterol. 40(5), 490-497 (2005). (Pubitemid 40823284)
90. Paulin R, Courboulin A, Meloche J et al. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation 123(11), 1205-1215 (2011).
91. Courboulin A, Paulin R, Giguère NJ et al. Role for miR-204 in human pulmonary arterial hypertension. J. Exp. Med. 208(3), 535-548 (2011).
92. Brock M, Trenkmann M, Gay RE et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ. Res. 104(10), 1184-1191 (2009).
93. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell 109, S67-S79 (2002). (Pubitemid 34457853)
94. Bonnet S, Paulin R, Sutendra G et al. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-β/NFAT axis. Circulation 120(13), 1231-1240 (2009).
95. Paulin R, Meloche J, Jacob MH, Bisserier M, Courboulin A, Bonnet S. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 301(5), H1798-H1809 (2011).
96. Homma N, Nagaoka T, Karoor V et al. Involvement of RhoA/Rho kinase signaling in protection against monocrotalineinduced pulmonary hypertension in pneumonectomized rats by dehydroepian-drosterone. Am. J. Physiol. Lung Cell Mol. Physiol. 295(1), L71-L78 (2008).
97. Dumas De La Roque E, Savineau J-P, Metivier A-C et al. Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study. Ann. Endocrinol. (Paris) 73(1), 20-25 (2012).
98. Bonnet S, Rochefort G, Sutendra G et al. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc. Natl Acad. Sci. USA 104(27), 11418-11423 (2007). (Pubitemid 47175155)
99. Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 22(2), 358-363 (2003). (Pubitemid 36987011)
100. Fujita M, Shannon JM, Irvin CG et al. Overexpression of tumor necrosis factor-α produces an increase in lung volumes and pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 280(1), L39-L49 (2001).
101. Wang Q, Zuo XR, Wang YY, Xie WP, Wang H, Zhang M. Monocrotalineinduced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats. Vascul. Pharmacol. 58(1-2), 71-77 (2013).
102. Kherbeck N, Tamby MC, Bussone G et al. The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension. Clin. Rev. Allergy Immunol. (2011).
103. Balabanian K, Foussat A, Dorfmüller P et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 165(10), 1419-1425 (2002). (Pubitemid 34522947)
104. Heresi GA, Aytekin M, Newman J, Dweik RA. CXC-chemokine ligand 10 in idiopathic pulmonary arterial hypertension: marker of improved survival. Lung 188(3), 191-197 (2010).
105. Sanchez O, Marcos E, Perros F et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 176(10), 1041-1047 (2007). (Pubitemid 350127849)
106. Ohta-Ogo K, Hao H, Ishibashi-Ueda H et al. CD44 expression in plexiform lesions of idiopathic pulmonary arterial hypertension. Pathol. Int. 62(4), 219-225 (2012).
107. Perros F, Dorfmüller P, Souza R et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur. Respir. J. 29(3), 462-468 (2007). (Pubitemid 46372091)
108. Jais X, Launay D, Yaici A et al. Immunosuppressive therapy in lupus-and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 58(2), 521-531 (2008). (Pubitemid 351294886)
109. Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ. J. 75(11), 2668-2674 (2011).
110. Voelkel NF, Tuder RM, Bridges J, Arend WP. Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am. J. Respir. Cell Mol. Biol. 11(6), 664-675 (1994).
111. Price LC, Montani D, Tcherakian C et al. Dexamethasone reverses monocrotalineinduced pulmonary arterial hypertension in rats. Eur. Respir. J. 37(4), 813-822 (2011).
112. Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 54(3), 273-277 (1999). (Pubitemid 29110511)
113. Caruso P, MacLean MR, Khanin R et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler. Thromb. Vasc. Biol. 30(4), 716-723 (2010).
114. Wu JH, Goswami R, Cai X et al. Regulation of the platelet-derived growth factor receptor-β by G protein-coupled receptor kinase-5 in vascular smooth muscle cells involves the phosphatase Shp2. J. Biol. Chem. 281(49), 37758-37772 (2006). (Pubitemid 46042079)
115. Senis YA, Tomlinson MG, Ellison S et al. The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis. Blood 113(20), 4942-4954 (2009).
116. Mizuno S, Bogaard HJ, Kraskauskas D et al. p53 Gene deficiency promotes hypoxia-induced pulmonary hypertension and vascular remodeling in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 300(5), L753-L761 (2011).
117. Giannakakis A, Sandaltzopoulos R, Greshock J et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol. Ther. 7(2), 255-264 (2008). (Pubitemid 351590433)
118. Fasanaro P, Greco S, Lorenzi M et al. An integrated approach for experimental target identification of hypoxia-induced miR-210. J. Biol. Chem. 284(50), 35134-35143 (2009).
119. Drake JI, Bogaard HJ, Mizuno S et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 45(6), 1239-1247 (2011).
120. Bonnet S, Archer SL, Allalunis-Turner J et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11(1), 37-51 (2007). (Pubitemid 46054520)
121. Lambert CM, Roy M, Robitaille GA, Richard DE, Bonnet S. HIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanism. Cardiovasc. Res. 88(1), 196-204 (2010).
122. Bonnet S, Michelakis ED, Porter CJ et al. An abnormal mitochondrial-hypoxia inducible factor-1α-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 113(22), 2630-2641 (2006). (Pubitemid 43948012)
123. Greenberger LM, Horak ID, Filpula D et al. A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth. Mol. Cancer Ther. 7(11), 3598-3608 (2008).
124. Sutendra G, Bonnet S, Rochefort G et al. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci. Transl. Med. 2(44), 44-58 (2010).
125. McMurtry MS, Bonnet S, Wu X et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cellapoptosis. Circ. Res. 95(8), 830-840 (2004). (Pubitemid 39390586)
126. Pozeg ZI, Michelakis ED, McMurtry MS et al. In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 107(15), 2037-2044 (2003). (Pubitemid 36506080)
127. McMurtry MS, Archer SL, Altieri DC et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Invest. 115(6), 1479-1491 (2005). (Pubitemid 40814657)
128. Mainguy V, Maltais F, Saey D et al. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax 65(2), 113-117 (2010).
129. Clinicaltrials.gov. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension (PAH), Novartis. http://clinicaltrials.gov/ct2/show/NCT011 79737?term=NCT01179737&rank=1
130. Clinicaltrials.gov. Dichloroacetate (DCA) for the treatment of pulmonary arterial hypertension, University of Alberta and the Imperial College London. http://clinicaltrials.gov/ct2/show/NCT010 83524?term=NCT01083524&rank=1